Cancer Immunotherapy Race Stays Unpredictable

Merck, Bristol-Myers and Roche head the race to pioneer PD-1 therapies.

Mar 7, 2014 at 11:00AM

Cancer immunotherapy is a very hot field, and Bristol-Myers Squibb (NYSE:BMY) certainly took note, reallocating resources late last year to focus on the field, selling off its diabetes arm to AstraZeneca and ending new research in diabetes, hepatitis C and neuroscience.

Now recent promising results on Bristol-Myers' PD-1 therapy nivolumab makes Bristol-Myers an even more competitive contender in an already very close race with big names Merck (NYSE:MRK) and Roche (NASDAQOTH:RHHBY).

PD-1 and PD-L1 (the ligand for the PD-1 receptor) agents work on proteins involved in programmed cell death of tumor cells. Journal of Clinical Oncology published March 3 research on nivolumab showing one and two year survival rates of 62% and 43%, 31% of patients showing objective tumor regression and a two year median response duration. This study examined advanced, treatment-refractory melanoma patients, making the response all the more impressive .

The big three: Merck, Bristol-Myers and Roche
The PD-1 race is a hot one, which Merck will likely lead, planning for submission to the FDA this summer. Merck had made MK-3475 a cornerstone of its expansion into cancer immunotherapy, hoping that the program will yield a success to end its drought of new drug approvals. Besides multiple early stage studies of MK-3475 in various tumor types in-house, it recently went on a slew of partnerships to study combination therapies for different cancers. Of these, Merck partnered with Incyte (NASDAQ:INCY) to examine a combination of MK-3475 with Incyte's INCB24360 in non-small cell lung cancers, and with Amgen (NASDAQ:AMGN) to look at MK-3475 with talimogene laherparepvec.

Bristol-Myers is not by any means an underdog in this race, but the company's decision in late January to continue Phase II studies of its nivolumab and Yervoy combination rather than going to Phase III studies caused much criticism from investors yearning to make Bristol-Myers the first to a PD-1 therapeutic. The rationale behind Bristol-Myers' conservative approach was not clear as data from the study will not be released until this summer at the ASCO conference, but investors clearly took it for the worst as shares dropped nearly 6%, the biggest single-day drop since August of 2012.

BMY Chart

BMY data by YCharts

Interestingly, it was this Yervoy-nivolumab combination that really first set off the field when it showed a 40% response rate in melanoma last summer at ASCO. At the time, Merck was still fumbling to show much positive data and it was Bristol-Myers and Roche's MPDL3280A for non-small cell lung cancer that were seen as the frontrunners.

Since last fall, however, Roche has not released much in the way of new data for its agent. MPDL3280A is the only agent among the three leaders that operates on PD-L1 rather than PD-1, the latter being the receptor for which the former acts on.

Roche has, however, suffered a couple setbacks this year that may hurt investor confidence on its R&D success. The same day as Bristol-Myers' announcement of nivolumab's success in melanoma, Roche had a separate lung cancer therapy, MetMab combined with Tarceva, fail to block tumor growth in late-stage trials.

Nonetheless, Roche is looking pretty strong as the $16.3 billion in operating cash flow last year pays down its 2009 Genentech purchase and opens up the possibility for more dealmaking and R&D.

Bottom Line
Looking at just the PD-1 race, Merck looks like it is certainly trying the hardest, with the aggressive pace at which it is rolling on MK-3475 projects. However, Merck suffers from a lack of empiricism when it comes to R&D, and the quick pace may be a result of desperation more than it is actual confidence -- this project is very important to the company.

Roche is historically strong in oncology, but had a couple recent setbacks in R&D and still needs to focus on building its cash reserves following the $47 billion Genentech acquisition. In the meantime, it has remained largely quiet about MPDL3280A as of late as compared to rivals Merck and Bristol-Myers, perhaps accepting its place lagging the two for a PD-1 therapy.

On the other hand, Bristol-Myers' great earnings reports, successful cost-cutting measures, new product launches (i.e. Eliquis) and strong sales (I.e. of Yervoy and Sprycel) put it in a very strong position as a company. When it comes to its PD-1 program, it does not need to make it a cornerstone project like Merck does, and it can afford to be more conservative in development.

However, the PD-1 race is a very competitive one and perhaps the recent study in advanced melanoma will spur Bristol-Myers to speed ahead on nivolumab. Bristol-Myers appears to have a very viable product on its hands and when it comes to R&D, empiricism and reputation is on its side.

Another great investment opportunity
Opportunities to get wealthy from a single investment don't come around often, but they do exist, and our chief technology officer believes he's found one. In this free report, Jeremy Phillips shares the single company that he believes could transform not only your portfolio, but your entire life. To learn the identity of this stock for free and see why Jeremy is putting more than $100,000 of his own money into it, all you have to do is click here now.

Amy Ho has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers